Quick Answer
Damora Therapeutics, Inc. reported Operating Income of -$210.87 million for fiscal year 2025.
Damora Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$210.87M | -847.3% |
| 2024 | -$22.26M | +44.2% |
| 2023 | -$39.91M | +34.8% |
| 2022 | -$61.21M | -17.2% |
| 2021 | -$52.23M | -55.3% |
| 2020 | -$33.64M | -186.3% |
| 2019 | $38.97M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.16M | +17.8% | +7.7% |
| June 30, 2025 | -$3.42M | +38.7% | -31.6% |
| March 31, 2025 | -$2.60M | +54.7% | +32.3% |
| September 30, 2024 | -$3.84M | +55.3% | +31.1% |
| June 30, 2024 | -$5.58M | +50.0% | +2.9% |
| March 31, 2024 | -$5.74M | +57.4% | +33.1% |
| September 30, 2023 | -$8.58M | +37.0% | +23.1% |
| June 30, 2023 | -$11.16M | +34.8% | +17.3% |
- Damora Therapeutics, Inc. showed a decrease of -847.3% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Damora Therapeutics, Inc.’s operating income has declined by 641.1% (from $38.97 million to -$210.87 million).
- The most recent figure is from Damora Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: